新工艺制备的咳喘六味合剂治疗哮喘小鼠的作用机制研究

Abstract
Figure/Table
References (29)
Related Citation (15)

Download: PDF (837 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of Kechuanliuwei Oral Liquid prepared by new technology on asthmatic mice and to explore its anti-asthma mechanism. Methods According to the random number table method, the mice were divided into control group, asthma model group, Kechuanliuwei Oral Liquid (new technology) low-dose group (15.5 g/kg), Kechuanliuwei Oral Liquid (new technology) high-dose group (31 g/kg), Dexamethasone group (3 g/kg), with six mice in each group. Except for control group, the other groups were treated with ovalbumin (OVA) to establish asthma model. Each group was given intragastric administration of drug from day 21 of modeling, at the same time, atomization excitation was given. Airway reactivity was measured by pulmonary function meter; pathological changes of lung tissue were observed by HE staining; serum interleukin (IL)-13, IL-17 and interferon-γ (IFN-γ) were measured by enzyme-linked immunosorbent assay. Results Asthma model group, Kechuanliuwei Oral Liquid (new technology) low-dose group, Kechuanliuwei Oral Liquid (new technology) high-dose group and Dexamethasone group were all successfully atomized to induce asthma. When Acetylcholine concentration was 6.250, 12.500, 50.000 mg/ml, the Penh value of asthma model group were higher than those of control group, and the differences were statistically significant (P < 0.05); Penh values of Kechuanliuwei Oral Liquid (new technology) low-dose group, Kechuanliuwei Oral Liquid (new technology) high-dose group and Dexamethasone group were lower than those of asthma model group, and the differences were statistically significant (P < 0.05). In control group, the lung tissue structure was clear and complete, and the bronchus and alveoli were normal, without obvious inflammatory cells. In asthmatic model group, the lung tissue structure was disordered, and the bronchus became narrow and thick, surrounded by inflammatory cells. The lung tissues of mice in Kechuanliuwei Oral Liquid (new technology) low-dose group, Kechuanliuwei Oral Liquid (new technology) high-dose group and Dexamethasone group were slightly changed with good structure; and the bronchus were all deformed to different degrees, but the degree of narrowing and thickening was less than that of asthma model group, and there were a few inflammatory cells. There were no significant differences in serum IL-13, IL-17, and IFN-γ levels between asthma model group and control group (P > 0.05). The serum levels of IL-13, IL-17, and IFN-γ in Kechuanliuwei Oral Liquid (new technology) low-dose group, Kechuanliuwei Oral Liquid (new technology) high-dose group and Dexamethasone group were not significantly different from those in asthma model group (P > 0.05). Conclusion Kechuanliuwei Oral Liquid prepared by new technology can improve the airway reactivity, pathological damage of lung tissue and inflammatory response in asthmatic mice.

Key words： Kechuanliuwei Oral Liquid Asthma Airway reactivity Interferon -γ Interleukin-13 Interleukin-17

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Fanping XI Yan▲

Cite this article:

YANG Fanping XI Yan▲. Study on the mechanism of Kechuanliuwei Oral Liquid prepared by new technology in the treatment of asthmatic mice[J]. 中国医药导报, 2021, 18(22): 37-40,45.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I22/37

[1] Global strategy for asthma management and prevention. Global Initiative for Asthma（GINA）. 2016. http：www.ginasthma.org.
[2] 廖小刚，朱爱勇，王欣国，等.中国成人哮喘患病率的Meta分析[J].中国循证医学杂志，2020，20（10）：1164-1172.
[3] 吕巧玉，麻文菁，陶孟瑶，等.小青龙汤治疗支气管哮喘研究进展[J].中国处方药，2021，19（2）：26-28.
[4] Matinez FD，Vercelli D. Asthma [J]. Lancet，2013，382（9901）：1360-1372.
[5] 倪伟，吴银根，张惠勇，等.咳喘落治疗支气管哮喘寒哮证多中心临床研究[J].上海中医药大学学报，2007，21（3）：43-45.
[6] 邹璐，方泓.咳喘六味合剂治疗寒哮型支气管哮喘的临床评价[J].上海中医药大学学报，2017，31（4）：24-27.
[7] 杨帆平，李国文，奚燕，等.咳喘六味合剂质量标准提高研究[J].药学实践杂志，2019，38（1）：55-59.
[8] 丁子桐，苗丰，高琴琴，等.桂芍子喘颗粒对卵蛋白所致支气管哮喘小鼠的药效学研究[J].中国药师，2020，23（8）：1498-1503.
[9] 史芝英，潘颖宜，符胜光，等.热哮方治疗支气管哮喘药效学的研究[J].上海中医药大学学报，2002，16（3）：57-58.
[10] 符冰，刘锐锋，唐蕾，等.梨杷止咳合剂药效学研究[J].中国药业，2020，29（23）：18-20.
[11] 李美容，王敏.哮喘小鼠模型的建立与评价[J].临床肺科杂志，2011，16（5）：664-665.
[12] 胡婕，邹文静，王韵婷，等.经口气管插管激发和雾化激发建立哮喘小鼠模型的比较[J].中国临床解剖学杂志，2021，39（1）：65-70.
[13] 杜军，郭宏伟，邓家刚.哮喘小鼠模型研究现状分析[J].中国免疫学杂志，2011，27（12）：1209-1211.
[14] 徐静，金晓洁，缪志海，等.支气管哮喘小鼠细胞免疫因子及Th17细胞水平的变化及发病机制研究[J].浙江医学，2018，40（3）：221-223.
[15] 杨军霞，郭英萌.阿奇霉素对哮喘小鼠气道炎症及细胞因子表达的影响[J].中国医药导报，2019，16（18）：21-24.
[16] 付宗强，牛小斌，张汇征，等.小鼠过敏性哮喘模型肺组织中Th9细胞相关因子的变化及意义[J].实验与检验医学，2020，38（4）：626-629.
[17] Lim JC，Goh FY，Sagineedu SR，et al. A semisynthetic diterpenoid lactone inhibits NF-κB signalling to ameliorate inflammation and airway hyperresponsiveness in a mouse asthma model [J]. Toxicol Appl Pharmacol，2016， 302：10-22.
[18] 李斯南，朱述阳，罗涛，等.吸入激素联合噻托溴铵治疗哮喘-慢性阻塞性肺疾病重叠综合征的效果及对血清炎症因子水平的影响[J].临床和实验医学杂志，2019， 18（16）：1748-1751.
[19] Bosnjak B，Stelzmueller B，Erb KJ，et al. Treatment of allergic asthma modulation of Th2 cells and their responses [J]. Respir Res，2011，12（1）：114.
[20] 邱伟群，陈东锋，许为钊，等.孟鲁司特结合普米克令舒对哮喘患者疗效、肺功能及T淋巴细胞亚群的影响研究[J].中国医药科学，2020，10（6）：66-68.
[21] 万斯慜，张进，芦爱萍.白细胞介素与哮喘发病机制的研究进展[J].医学综述，2011，17（6）：820-822.
[22] 郑明昱，金哲悟，朴红梅，等.红景天苷通过NF-κB/TGF-β1信号通路抑制哮喘小鼠气道重塑的实验研究[J].中草药，2014，45（17）：2511-2516.
[23] 林伟军，吕聪聪，张怡丹，等.孟鲁司特联合沙丁胺醇对哮喘患儿血清TNF-α、IL-10、IL-13因子水平的影响[J].中国现代医生，2021，59（2）：63-66.
[24] 张雪，潘家华.IL-17在哮喘发病机制中免疫作用的研究进展[J].安徽医药，2012，16（12）：1743-1746.
[25] 钱星佳，吕红，陆兵，等.风痰方介导TLR2TH17IL-17应答轴治疗咳嗽变异性哮喘的新机制研究[J].中外医学研究，2021，19（13）：29-31.
[26] 邹璐，孙祝美，郭春荣，等.中医药防治支气管哮喘气道重塑相关信号通路研究进展[J].中华中医药杂志，2018， 33（11）：5057-5060.
[27] 许杰红，曹厚然，陈玉兴.中药单剂炙麻黄、麻黄对哮喘大鼠气道炎症反应的影响[J].新中医，2014，46（12）：197-199.
[28] 韩超，杨柳，张秋玲，等.黄芩苷抗哮喘作用与HMGB1/TLR4传导通路的相关性研究[J].世界中医药，2019，14（6）：1402-1407.
[29] 王珏，李竹英.刘建秋教授运用药对治疗支气管哮喘经验[J].中国中医急症，2020，29（6）：1102-1104.